This title appears in the Scientific Report :
2019
Please use the identifier:
http://dx.doi.org/10.1007/s11060-019-03246-4 in citations.
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
PurposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we...
Saved in:
Personal Name(s): | Kebir, Sied (Corresponding author) |
---|---|
Schaub, Christina / Junold, Nina / Hattingen, Elke / Schäfer, Niklas / Steinbach, Joachim P. / Weyerbrock, Astrid / Hau, Peter / Goldbrunner, Roland / Galldiks, Norbert / Weller, Johannes / Mack, Frederic / Tzaridis, Theophilos / Bähr, Oliver / Seidel, Clemens / Schlegel, Uwe / Schmidt-Graf, Friederike / Rohde, Veit / Borchers, Christian / Tabatabai, Ghazaleh / Hänel, Mathias / Sabel, Michael / Gerlach, Rüdiger / Krex, Dietmar / Belka, Claus / Vatter, Hartmut / Proescholdt, Martin / Glas, Martin / Herrlinger, Ulrich | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | Journal of neuro-oncology, 144 (2019) 3, S. 501-509 |
Imprint: |
Dordrecht [u.a.]
Springer Science + Business Media B.V
2019
|
DOI: |
10.1007/s11060-019-03246-4 |
PubMed ID: |
31325144 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity |
Publikationsportal JuSER |
PurposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset.MethodsMRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival.ResultsMRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival.ConclusionsBaseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide. |